TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10170460

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 5 micrograms/kg/day
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 154
Study: 1585296

Group type: EXPERIMENTAL
Intervention: 10 mg temazepam
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 4055206

Group type: EXPERIMENTAL
Intervention: General practitioner counselling and follow-up in a smoking cessation programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attendance at first three visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuing smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction in stated cigarette consumption
Number of subjects: 0
Study: 31326055

Group type: EXPERIMENTAL
Intervention: Cryotherapy application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30266270

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus plantarum P8 (10 log CFU daily)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 28470492

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (30 mL for 90 days)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Olive oil (30 mL for 90 days)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Sunflower oil (30 mL for 90 days)
Number of subjects: 79
Study: 25423324

Group type: EXPERIMENTAL
Intervention: Outdoor training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Indoor training
Number of subjects: 23
Study: 23756301

Group type: EXPERIMENTAL
Intervention: Gray mineral trioxide aggregate (GMTA)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Diluted formocresol (DFC)
Number of subjects: 152
Study: 20856256

Group type: COMPARATOR
Intervention: Caloric restriction only (CR)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Caloric restriction + moderate-intensity exercise (CR+moderate)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Caloric restriction + vigorous-intensity exercise (CR+vigorous)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: All interventions (CR, CR+moderate, CR+vigorous)
Number of subjects: 61
Study: 18300929

Group type: EXPERIMENTAL
Intervention: NDT-based trunk activation protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parent-infant interaction and play protocol (Control)
Number of subjects: 0
Study: 16931694

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (n = 25)
Number of subjects: 50
Study: 12917744

Group type: EXPERIMENTAL
Intervention: 100 g caffeine
Number of subjects: 30
Study: 10632642

Group type: EXPERIMENTAL
Intervention: Alosetron 2 mg b.d.
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Alosetron 0.5 mg b.d.
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 9443520

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg, p.o.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg, p.o.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8440100

Group type: EXPERIMENTAL
Intervention: Intermittent machine hemofiltration (4 hrs)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Continuous modes of renal replacement therapy (CAVH/CAVHD)
Number of subjects: 32
Study: 3734264

Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation with heparin
Number of subjects: 90

Group type: COMPARATOR
Intervention: No anticoagulant therapy
Number of subjects: 90
Study: 28610442

Group type: EXPERIMENTAL
Intervention: Corrective functional exercise program
Number of subjects: 164

Group type: COMPARATOR
Intervention: State-regulated curriculum exercise program (Control)
Number of subjects: 164
Study: 27650406

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 20‐70 mg/day, n=25
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo, n=25
Number of subjects: 50
Study: 24018777

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment at 1-month interval
Number of subjects: 13

Group type: COMPARATOR
Intervention: Fractional CO2 laser treatment at 3-month interval
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both treatment intervals (1-month and 3-month)
Number of subjects: 13
Study: 23169469

Group type: EXPERIMENTAL
Intervention: Prophylactic PEG for early enteral feeding
Number of subjects: 134

Group type: COMPARATOR
Intervention: Nutritional care according to clinical praxis
Number of subjects: 134
Study: 20484640

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) delivered at different times before grasping the object.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual cues about object weight available during grasping.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticospinal excitability (CSE) changes assessed by TMS.
Number of subjects: 0
Study: 18679142

Group type: EXPERIMENTAL
Intervention: Calfactant
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 16809072

Group type: EXPERIMENTAL
Intervention: Treatment as allocated (specific intervention details not available)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Video observations
Number of subjects: 402
Study: 12954305

Group type: EXPERIMENTAL
Intervention: HSM PMMA IOL
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: AcrySof IOL
Number of subjects: 180
Study: 10996870

Group type: EXPERIMENTAL
Intervention: Regimen IR (isoniazid 300 mg daily and rifampin 600 mg daily)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Regimen I (isoniazid 300 mg daily for 12 months)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Regimen IR
Number of subjects: 133

Group type: COMPARATOR
Intervention: Regimen I
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 133
Study: 7706541

Group type: EXPERIMENTAL
Intervention: Colgate Paradent (triclosan/copolymer dentifrice)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Pepsodent Gum Health (triclosan/zinc citrate dentifrice)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Dentosal Friskt Tandkött (triclosan/pyrophosphate dentifrice)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo (sodium monofluorophosphate dentifrice)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Colgate Paradent
Number of subjects: 123

Group type: COMPARATOR
Intervention: Dentosal, Pepsodent, and placebo groups
Number of subjects: 123
Study: 2693621

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPN) 125mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Metoclopramide (MCP) 20mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPN)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Methylprednisolone (MPN) and Metoclopramide (MCP)
Number of subjects: 19
Study: 367794

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 30865775

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 100
Study: 31303261

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 28535785

Group type: EXPERIMENTAL
Intervention: Targeted medication therapy management (MTM) intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 25468397

Group type: EXPERIMENTAL
Intervention: Communication skills training for primary care doctors
Number of subjects: 379

Group type: COMPARATOR
Intervention: Usual care controls
Number of subjects: 379
Study: 22874533

Group type: EXPERIMENTAL
Intervention: Breakfast Quality Index (BQI) score
Number of subjects: 4332
Study: 21036454

Group type: EXPERIMENTAL
Intervention: Phone CPR (guided intervention)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No phone CPR (non-guided intervention)
Number of subjects: 110
Study: 18311814

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic intervention to reduce pain
Number of subjects: 10
Study: 16781381

Group type: COMPARATOR
Intervention: Left atrial ablation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Biatrial ablation
Number of subjects: 80
Study: 12703850

Group type: EXPERIMENTAL
Intervention: Resistance training (3 times a week for 9 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 23
Study: 10896016

Group type: EXPERIMENTAL
Intervention: Scapula manually stabilized
Number of subjects: 50

Group type: COMPARATOR
Intervention: Scapula unstabilized
Number of subjects: 50
Study: 9282768

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 210
Study: 8419602

Group type: EXPERIMENTAL
Intervention: Nebulized racemic epinephrine, 0.1 ml/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nebulized salbutamol, 0.03 ml/kg
Number of subjects: 24
Study: 3523368

Group type: EXPERIMENTAL
Intervention: tixocortol pivalate-neomycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: neomycin
Number of subjects: 60
Study: 31311595

Group type: EXPERIMENTAL
Intervention: Real multimodal group (RMG) - multimodal physical exercises in a real environment, 2 times per week for 60 minutes per session for 15 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Virtual multimodal group (VMG) - multimodal physical exercises in a virtual environment, 2 times per week for 60 minutes per session for 15 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined multimodal group (CMG) - one session in a real environment and one session in a virtual environment per week for 15 weeks
Number of subjects: 36
Study: 29630789

Group type: EXPERIMENTAL
Intervention: Anhydrous 0.454% SnF2 dentifrice containing 5% sodium tripolyphosphate (STP)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Standard fluoride dentifrice (0.76% fluoride as sodium monofluorophosphate [SMFP])
Number of subjects: 214
Study: 27005290

Group type: EXPERIMENTAL
Intervention: Local wound infiltration plus TAP block
Number of subjects: 48

Group type: COMPARATOR
Intervention: Local wound infiltration
Number of subjects: 48
Study: 25257687

Group type: EXPERIMENTAL
Intervention: Pharmacist-led Diabetes Management Education Program (DMEP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard pharmacy care (control group)
Number of subjects: 8
Study: 23342780

Group type: EXPERIMENTAL
Intervention: Scalp-acupoint catgut embedding, once a week for 4 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine acupuncture, 3 times a week for 4 weeks
Number of subjects: 64
Study: 20157180

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 200 mg/m2 (n=15)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 375 mg/m2 (n=16)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 375 mg/m2 first dose, then 750 mg/m2 (n=16)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (all cohorts)
Number of subjects: 47
Study: 18413070

Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) in frozen-thawed embryo transfer cycles
Number of subjects: 960

Group type: COMPARATOR
Intervention: Control group (no assisted hatching) in frozen-thawed embryo transfer cycles
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) in fresh embryo transfer cycles
Number of subjects: 960

Group type: COMPARATOR
Intervention: Control group (no assisted hatching) in fresh embryo transfer cycles
Number of subjects: 960
Study: 16006914

Group type: EXPERIMENTAL
Intervention: 20 mg trospium chloride twice daily
Number of subjects: 658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study: 11952288

Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of 100 units of Botulinum toxin A (BTXA) on the more severely affected hand
Number of subjects: 8

Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 8
Study: 10631405

Group type: EXPERIMENTAL
Intervention: Perennial allergic rhinitis
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Perennial nonallergic rhinitis
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 34
Study: 8636336

Group type: EXPERIMENTAL
Intervention: Recombinant human GH at 0.33 IU/m(2)-day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recombinant human GH at 0.66 IU/m(2)-day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recombinant human GH at 1.0 IU/m(2)-day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recombinant human GH at 2.0 IU/m(2)-day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recombinant human GH at 3.0 IU/m(2)-day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (various doses)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (optimal dose)
Number of subjects: 46
Study: 1355765

Group type: EXPERIMENTAL
Intervention: Norethindrone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Levonorgestrel
Number of subjects: 72
Study: 6386488

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mgs
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Guanfacine 2 mgs
Number of subjects: 6
Study: 30636111

Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MED)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Metabolic syndrome (MetS) women
Number of subjects: 246

Group type: COMPARATOR
Intervention: Metabolic syndrome (MetS) men
Number of subjects: 246
Study: 30111472

Group type: EXPERIMENTAL
Intervention: L-carnitine treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 120
Study: 27285946

Group type: EXPERIMENTAL
Intervention: Permanently implantable wireless pulmonary artery pressure monitoring system
Number of subjects: 0
Study: 24614759

Group type: EXPERIMENTAL
Intervention: F-genotype attenuated mumps vaccine A (3.5 ± 0.25 logCCID50)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: F-genotype attenuated mumps vaccine B (4.25 ± 0.25 logCCID50)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: F-genotype attenuated mumps vaccine C (5.0 ± 0.25 logCCID50)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 300

Group type: COMPARATOR
Intervention: Positive control (licensed A-genotype vaccine S79 strain)
Number of subjects: 300
Study: 22327773

Group type: EXPERIMENTAL
Intervention: Cotton gauze dressing removed 48 hours after surgery
Number of subjects: 230

Group type: COMPARATOR
Intervention: Cotton gauze dressing kept on for 7-8 days until removal of skin sutures (Control)
Number of subjects: 230
Study: 20216563

Group type: EXPERIMENTAL
Intervention: Food plus micronutrient capsule (MN) containing 15 mg zinc/day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Food supplement
Number of subjects: 81
Study: 18381791

Group type: EXPERIMENTAL
Intervention: Fulvestrant (250 mg intramuscularly for 12 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16011383

Group type: EXPERIMENTAL
Intervention: Motivational interview
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Reduction of logistical barriers to attendance
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 195

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 195
Study: 12407863

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirofiban and Integrilin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed treatment scheme including clopidogrel and abciximab
Number of subjects: 0
Study: 10597334

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab (retreatment)
Number of subjects: 0
Study: 7488808

Group type: EXPERIMENTAL
Intervention: Energy-dense porridge liquefied with amylase-rich flour (ARF)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Thick unaltered porridge (Control Group 2)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Porridge diluted with water (Control Group 3)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Energy-dense porridge liquefied with ARF
Number of subjects: 66
Study: 1823527

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7387805

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyoscine
Number of subjects: 0
Study: 29512468

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic BP target of <120 mmHg)
Number of subjects: 1562

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic BP target of <120 mmHg) with low baseline SBP (<150 mmHg)
Number of subjects: 1562

Group type: COMPARATOR
Intervention: Standard treatment (systolic BP target of <140 mmHg)
Number of subjects: 1562
Study: 29042830

Group type: EXPERIMENTAL
Intervention: 500 mg A-GPC
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 250 mg A-GPC
Number of subjects: 48

Group type: COMPARATOR
Intervention: 200 mg Caffeine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24986062

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study: 24492985

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)/Amlodipine besylate (AM)/Hydrochlorothiazide (HCTZ) 40/10/25 mg
Number of subjects: 40
Study: 22806822

Group type: EXPERIMENTAL
Intervention: Bupropion 100-150 mg/day (100 mg/day for <30 kg and 150 mg/day for >30 kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Methylphenidate 20-30 mg/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 44
Study: 20506064

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 68
Study: 17359606

Group type: EXPERIMENTAL
Intervention: Primary care mental health workers
Number of subjects: 368

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 368
Study: 15734768

Group type: EXPERIMENTAL
Intervention: Complete SigmaSTR (>=70%) and MB grade 2/3
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Incomplete SigmaSTR (<70%) and reduced MB (grade 0/1)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Discordant MB and SigmaSTR
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: SigmaSTR
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: MB
Number of subjects: 456
Study: 11989995

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 45
Study: 9783884

Group type: EXPERIMENTAL
Intervention: Nicotinamide (NAM)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Carbogen
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no flow modulator)
Number of subjects: 19
Study: 7863824

Group type: EXPERIMENTAL
Intervention: Patients with previous femur shaft fracture
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal men (control group)
Number of subjects: 29
Study: 2648763

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution with sodium concentration of 35 mmol/l and dextrose of 200 mmol/l
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution with sodium concentration of 50 mmol/l and dextrose of 111 mmol/l
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution with sodium concentration of 90 mmol/l and dextrose of 110 mmol/l
Number of subjects: 269
Study: 29394109

Group type: EXPERIMENTAL
Intervention: MobileKids Monster Manor (MKMM)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status environment
Number of subjects: 37
Study: 27807039

Group type: EXPERIMENTAL
Intervention: ASA24 dietary recall system
Number of subjects: 81

Group type: COMPARATOR
Intervention: Interviewer-administered Automated Multiple-Pass Method (AMPM) recall
Number of subjects: 81
Study: 25633661

Group type: EXPERIMENTAL
Intervention: Internet-based diabetes dashboard management tool
Number of subjects: 199
Study: 24640436

Group type: COMPARATOR
Intervention: OptiBond Solo Plus/Nexus Third Generation (NX3)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: XP Bond/SureFil SDR Flow (SDR)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vertise Flow (VF)
Number of subjects: 36
Study: 20619448

Group type: EXPERIMENTAL
Intervention: Self-management with telemonitoring (n=263)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Usual care (control) (n=264)
Number of subjects: 527
Study: 18788030

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 12
Study: 16914781

Group type: EXPERIMENTAL
Intervention: High-pressure suction drainage (600 mm Hg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-pressure suction drainage (350 mm Hg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 12506170

Group type: COMPARATOR
Intervention: Fluorouracil (FU) alone
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus cisplatin (FP)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Uracil and tegafur plus mitomycin (UFTM)
Number of subjects: 280
Study: 10948025

Group type: EXPERIMENTAL
Intervention: Homoeopathy (30c preparation of principal inhalant allergen)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Homoeopathy (combined with previous trials)
Number of subjects: 51
Study: 8655662

Group type: EXPERIMENTAL
Intervention: High feedback
Number of subjects: 211

Group type: COMPARATOR
Intervention: Low feedback
Number of subjects: 211